ACTION

Our Campaigns

Improving Health Care

In addition to providing the patient perspective to decision-makers, CBCN also works to engage with health technology assessment (HTA) bodies to influence regulatory policies and promote patient-centered approaches to decision-making.

CBCN routinely connects with agencies like the Canadian Agency for Drugs and Technologies in Health (CADTH), the pan-Canadian Oncology Drug Review (pCODR), Common Drug Review (CDR), pan-Canadian Pharmaceutical Alliance (pCPA), and provincial bodies to promote reforms to the overall process by which health care decisions are made and to support optimal outcomes for Canadian patients and their families.

Our key objectives in engaging Canadian assessment bodies are to promote:

  1. Greater transparency and accountability by Canadian health agencies. CBCN supports initiatives and recommendations that will lead to timely decision-making around health and increased clarity around decisions and the impacts they will have on Canadians.
     
  2. Increased opportunities for patient engagement throughout the healthcare system. CBCN believes that patient values should inform health care decision-making and we actively work to ensure that the patient voice is being leveraged to support effective regulatory policies.

Timeline of drug review and approvals process in Canada

SHARE

Medsearch

Where metastatic drugs are available in Canada

Quick Find

Our Stories

Events

See our calendar